Advertisement

Ads Placeholder
Loading...

Alkermes plc

ALKS•NASDAQ
Healthcare
Biotechnology
$34.84
$-0.21(-0.60%)
U.S. Market opens in 27h 57m

Alkermes plc (ALKS) Stock Overview

Explore Alkermes plc’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap5.8B
P/E Ratio23.74
EPS (TTM)$1.43
ROE0.14%
Fundamental Analysis

AI Price Forecasts

1 Month$27.00
3 Months$27.57
1 Year Target$30.20

ALKS Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Alkermes plc (ALKS) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of A, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 70.84, suggesting the stock is in an overbought condition. Our forecasting models predict significant price movements, with a 12-month target of $30.20.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 23.74 and a market capitalization of 5.8B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
-0.60%
5-Day Change
16.52%
1-Month Change
19.32%
3-Month Change
23.28%
6-Month Change
12.17%
Year-to-Date (YTD) Change
23.28%
1-Year Change
10.04%
3-Year Change
21.52%
5-Year Change
80.89%
All-Time (Max) Change
533.45%

Contact Information

https://www.alkermes.com
353 1 772 8000
Connaught House, Dublin, NaN, 4

Company Facts

18,000 Employees
IPO DateJul 16, 1991
CountryIE
Actively Trading

Frequently Asked Questions